GlassScriptPhysician profile
Kiumarce Kashi
NPI 1629081500
$10,005.02
in general payments reported to CMS, 2019-2025
38 companies · $2,786 in 2025
The $2,786 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $1,043 · 2021: $1,411 · 2022: $1,022 · 2023: $1,127 · 2024: $1,394 · 2025: $2,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,438 · Travel and Lodging: $695 · Consulting Fee: $150 · Education: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,438.44 |
| Travel and Lodging | $695.44 |
| Consulting Fee | $150.00 |
| Education | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,733.20 | 2023-2025 | Inspire |
| Novo Nordisk INC | $1,343.61 | 2019-2025 | Ozempic, Rybelsus |
| Jazz Pharmaceuticals INC. | $1,028.51 | 2019-2025 | |
| Lilly USA, LLC | $799.56 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $732.66 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Harmony Biosciences LLC | $726.08 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.01 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $523.01 | 2019-2024 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $324.07 | 2022-2025 | Sunosi |
| Abbvie INC. | $301.22 | 2021-2025 | |
| Abbott Laboratories | $293.30 | 2024-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $170.47 | 2020-2021 | |
| Allergan, INC. | $149.56 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $133.14 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $123.46 | 2023-2025 | Lumryz |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiumarce Kashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.